EVGN vs CDNA vs NTRA vs PACB

For growth investors, Evogene Ltd.

(EVGN) is the stronger pick with 50. 9% revenue growth year-over-year, versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). Analysts rate CareDx, Inc (CDNA) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -97. 9% for Evogene Ltd. (EVGN). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus EVGN's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 26β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 93% more volatile than NTRA relative to the S&P 500. On balance sheet safety, CareDx, Inc (CDNA) carries a lower debt/equity ratio of 6% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evogene Ltd.

(EVGN) is pulling ahead at 50. 9% versus 3. 9% for Pacific Biosciences of California, Inc. (PACB). On earnings-per-share growth, the picture is similar: Evogene Ltd. grew EPS 44. 7% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, EVGN leads at 109. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CareDx, Inc (CDNA) is the more profitable company, earning -5.

6% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDNA leads at -5. 5% versus -348. 5% for PACB. At the gross margin level — before operating expenses — CDNA leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NTRA: 19.

4% to $262. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, CareDx, Inc (CDNA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+385.

1% 10Y return). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDNA: +385. 1%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EVGN is a small-cap high-growth stock; CDNA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; PACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.